VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rocketman who wrote (6429)	2/9/1999 5:30:00 PM
From: margie	Read Replies (1) of 9719

Bristol Myers has restructured their agreement with EntreMed to develop angiostatin. "EntreMed will now take on responsibility of all pre-clinical research into angiostatin." "Bristol-Myers Squibb Ends Research On EntreMed's Anticancer Drug" by Michael Waldholz In the WSJ Interactive, (requires subscription) interactive.wsj.com "Bristol-Myers said it will retain the rights to develop and market a product based on angiostatin if research by EntreMed shows the agent to be effective in prehuman studies. But the drug maker said it will end most all its own laboratory research into the agent, focusing its basic cancer research efforts on the development of other agents." Waldholz was on CNBC. I only heard the end, but I think he said BMY couldn't duplicate the results.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next